Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 [Yahoo! Finance]
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: Yahoo! Finance
Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, Bolt now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the Company i
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- Bolt Biotherapeutics (NASDAQ:BOLT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Bolt Biotherapeutics (NASDAQ:BOLT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Bolt Biotherapeutics (NASDAQ:BOLT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
BOLT
Earnings
- 5/12/25 - Beat
BOLT
Analyst Actions
- 10/21/25 - HC Wainwright
BOLT
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- BOLT's page on the SEC website